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As Reig and co-authors state, the ARREST trial found that in adults with Staphylococcus aureus 
bacteraemia, 14 days’ adjunctive rifampicin had no significant effect on the composite primary 
endpoint of death or microbiologically-confirmed failure or recurrence through 12 weeks.1 However, 
contrary to their subsequent statements, rifampicin had no impact on treatment failure, only on 
recurrence, and the significant association between rifampicin and antibiotic-modifying adverse 
events and drug interactions was in the intention-to-treat population, not a sub-group. 
A single trial rarely provides a completely definitive answer, especially in a clinically heterogenous 
infection like S. aureus bacteraemia. ARREST cannot exclude the possibility of a patient sub-group 
who might benefit from rifampicin. Reig et al assert that patients with complicated, deep-seated 
infections may benefit from rifampicin and suggest we enrolled too few such patients. However, just 
130 (17%) participants had uncomplicated, intravenous catheter-related infections; the rest included 
301 (40%) with a deep-seated focus (40 endocarditis) and 139 (18%) with no established focus, a 
sub-group with particularly poor outcomes.2 Planned sub-group analysis found no significant 
interaction between the primary outcome and sub-groups defined by deep focus (P=0.10), 
endocarditis (P=0.13), or unestablished focus (P=0.30), at best weak evidence for rifampicin’s benefit 
in complicated infections. 
Indeed, 20 planned and exploratory sub-group analyses failed to identify benefits from rifampicin in 
any sub-group, with the possible exception of those treated initially with flucloxacillin alone, a 
finding of uncertain clinical relevance. As Reig et al note, the benefit was lost if vancomycin or 
another drug was added to flucloxacillin, or the sub-group was defined by any beta-lactam antibiotic. 
There are few clinically plausible explanations for these observations, leaving the possibility that 
when 20 sub-group analyses are conducted, one produces a p-value <0.05 by chance.  
We accept that one important limitation of ARREST was the small number of participants with 
infected prosthetic devices, and we regret not having collected more information on those excluded 
because rifampicin was considered mandatory. The question of whether rifampicin benefits these 
patients, and other sub-groups articulated by Reig et al and no doubt many others who treat this 
common and serious infection, will only be answered by further well-conducted, adequately 
powered trials. Such trials are urgently needed to improve the treatment of this and many other life-
threatening infectious diseases. However, our key point remains that ARREST has demonstrated 
unequivocally that adjunctive rifampicin provides no overall benefit over standard antibiotic therapy 
in unselected adults with S. aureus bacteraemia. 
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